Novartis Stock Forecast for 2023 - 2025 - 2030

Updated on 04/01/2023

Stock Rating
10
Price Target
CHF94.25
Consensus
Neutral
Upside
9.89%
Analysts
11
Stock Rating
10
Upside
9.89%
Analysts
11
Price Target
CHF94.25

Novartis Stock Forecast and Price Target

The average price target for Novartis's stock of CHF94.25 recently provided by eleven leading analysts would represent a 9.89% upside from its last closing price if reached. This potential increase is based on a high estimate of CHF113.80 and a low estimate of CHF75.39. If you are not interested in NOVN stock, you may still be interested in its competitors and their current standings.

CHF94.25

9.89% Upside

Hold
Hold

Novartis Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Novartis's Price has grown by 19.13%, rising from CHF84.06 to CHF100.14. In the following year, the 0 analysts surveyed believe that Novartis's Fair Value will decrease by 8.29%, reaching CHF91.84. According to professionals, by 2030, Novartis's Fair Value will have decreased by 7.62%, falling down to CHF92.50.

2022 Fair Value Forecast
CHF91.84
2023 Fair Value Forecast
CHF89.47
2024 Fair Value Forecast
CHF90.54
2025 Fair Value Forecast
CHF93.71
2026 Fair Value Forecast
CHF93.11
2027 Fair Value Forecast
CHF91.89
2028 Fair Value Forecast
CHF91.45
2029 Fair Value Forecast
CHF92.20
2030 Fair Value Forecast
CHF92.50
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly and Outperform 16
$343.42 Buy/Sell $333.19 16.48%
ABBV Stock Forecast AbbVie Outperform 10
$159.36 Buy/Sell $162.24 3.54%
AZN Stock Forecast AstraZeneca PLC Outperform 8
£11.25k Buy/Sell £153.20 -98.61%
ABT Stock Forecast Abbott Laboratories Outperform 10
$101.26 Buy/Sell $121.44 23.44%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$69.31 Buy/Sell $80.99 19.75%

Novartis Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Novartis's Revenue has grown by 8.63%, rising from CHF48.68B to CHF52.88B. In the following year, the 0 analysts surveyed believe that Novartis's Revenue will decrease by 4.57%, reaching CHF50.46B. According to professionals, by 2030, Novartis's Revenue will have decreased by 4.31%, falling down to CHF50.60B.

2022 Rev Forecast
CHF50.46B
2023 Rev Forecast
CHF49.91B
2024 Rev Forecast
CHF49.95B
2025 Rev Forecast
CHF50.92B
2026 Rev Forecast
CHF50.77B
2027 Rev Forecast
CHF50.48B
2028 Rev Forecast
CHF50.31B
2029 Rev Forecast
CHF50.51B
2030 Rev Forecast
CHF50.60B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMGN Stock Forecast Amgen Inc Hold 7
$241.75 Buy/Sell $268.00 14.99%
CSL Stock Forecast CSL Outperform 8
$288.30 Buy/Sell $231.47 -21.59%
EL Stock Forecast EssilorLuxottica Société ano... Outperform 7
176.10€ Buy/Sell 186.11€ 5.05%

Novartis Dividend per Share Forecast for 2023 - 2025 - 2030

In the last two years, Novartis's Dividend per Share has grown by 8.65%, rising from CHF3.12 to CHF3.39. The next year, 0 experts forecast that Novartis's Dividend per Share will decrease by 2.65%, reaching CHF3.30. In 2030, professionals predict that Novartis's Dividend per Share will decrease by 2.45%, reaching CHF3.31.

2022 DPS Forecast
CHF3.30
2023 DPS Forecast
CHF3.24
2024 DPS Forecast
CHF3.29
2025 DPS Forecast
CHF3.32
2026 DPS Forecast
CHF3.32
2027 DPS Forecast
CHF3.29
2028 DPS Forecast
CHF3.29
2029 DPS Forecast
CHF3.30
2030 DPS Forecast
CHF3.31
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BDX Stock Forecast Becton, Dickinson and Outperform 17
$247.48 Buy/Sell $268.00 11.12%
MMM Stock Forecast 3M Hold 16
$105.08 Buy/Sell $147.79 13.72%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.07k Buy/Sell ¥0.00 35.30%

Novartis Free Cash Flow Forecast for 2023 - 2025 - 2030

Novartis's Free Cash Flow has grown In the last two years, rising from CHF12.25B to CHF13.69B – a growth of 11.82%. For the next year, 0 analysts project Novartis's Free Cash Flow to drop by 8.70%, reaching CHF12.50B. By 2030, professionals believe that Novartis's Free Cash Flow will decrease by 8.19%, reaching CHF12.57B – a concerning trend for the company.

2022 FCF Forecast
CHF12.50B
2023 FCF Forecast
CHF12.51B
2024 FCF Forecast
CHF12.20B
2025 FCF Forecast
CHF12.69B
2026 FCF Forecast
CHF12.63B
2027 FCF Forecast
CHF12.60B
2028 FCF Forecast
CHF12.47B
2029 FCF Forecast
CHF12.54B
2030 FCF Forecast
CHF12.57B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAYN Stock Forecast Bayer Outperform 7
58.72€ Buy/Sell 74.54€ 28.58%
BAS Stock Forecast BASF Hold 11
48.36€ Buy/Sell 53.50€ 13.73%
CTVA Stock Forecast Corteva Inc Outperform 12
$60.29 Buy/Sell $73.12 21.08%

Novartis Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Novartis's Net Income has grown, rising from CHF11.73B to CHF24.02B – a growth of 104.75%. According to the 0 analysts polled, in the next year, Novartis's Net Income will fall by 29.15%, reaching CHF17.02B. By 2030, professionals believe that Novartis's Net Income will have decreased by 24.59%, falling to CHF18.11B.

2022 NI Forecast
CHF17.02B
2023 NI Forecast
CHF18.16B
2024 NI Forecast
CHF16.25B
2025 NI Forecast
CHF18.77B
2026 NI Forecast
CHF18.27B
2027 NI Forecast
CHF18.34B
2028 NI Forecast
CHF17.66B
2029 NI Forecast
CHF18.03B
2030 NI Forecast
CHF18.11B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BIIB Stock Forecast Biogen Inc Outperform 11
$278.03 Buy/Sell $322.44 16.89%
DD Stock Forecast DuPont de Nemours Outperform 17
$71.78 Buy/Sell $80.32 11.45%
ALC Stock Forecast Alcon Outperform 15
CHF66.18 Buy/Sell CHF0.00 30.51%

Novartis EBITDA Forecast for 2023 - 2025 - 2030

Novartis's EBITDA has seen impressive growth In the last two years, rising from CHF13.27B to CHF17.15B – a growth of 29.30%. According to 0 prominent analysts, Novartis's EBITDA will fall by 8.00% in the next year, reaching CHF15.78B. By 2030, professionals believe that Novartis's EBITDA will decrease by 7.18%, reaching CHF15.92B – a concerning trend for the company.

2022 EBITDA Forecast
CHF15.78B
2023 EBITDA Forecast
CHF15.03B
2024 EBITDA Forecast
CHF15.66B
2025 EBITDA Forecast
CHF16.17B
2026 EBITDA Forecast
CHF16.05B
2027 EBITDA Forecast
CHF15.71B
2028 EBITDA Forecast
CHF15.70B
2029 EBITDA Forecast
CHF15.85B
2030 EBITDA Forecast
CHF15.92B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.92k Buy/Sell ¥0.00 24.74%
BAX Stock Forecast Baxter International Inc Outperform 17
$40.56 Buy/Sell $60.73 43.00%
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$200.32 Buy/Sell $244.18 25.30%

Novartis EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Novartis's EBIT has grown by 32.54%, rising from CHF9.09B to CHF12.04B. In the following year, 0 experts forecast Novartis's EBIT will decrease by 7.68%, to CHF11.12B. In 2030, professionals predict that Novartis's EBIT will decrease by 6.86%, to CHF11.22B.

2022 EBIT Forecast
CHF11.12B
2023 EBIT Forecast
CHF10.53B
2024 EBIT Forecast
CHF11.06B
2025 EBIT Forecast
CHF11.39B
2026 EBIT Forecast
CHF11.31B
2027 EBIT Forecast
CHF11.05B
2028 EBIT Forecast
CHF11.05B
2029 EBIT Forecast
CHF11.17B
2030 EBIT Forecast
CHF11.22B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
4523 Stock Forecast Eisai Hold 18
¥8.15k Buy/Sell ¥0.00 -18.99%
CHD Stock Forecast Church & Dwight Co Inc Hold 11
$88.42 Buy/Sell $82.17 -3.87%
AFX Stock Forecast Carl Zeiss Meditec Outperform 18
128.00€ Buy/Sell 140.27€ 5.47%

Novartis EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Novartis's EPS has grown by 19.13%, rising from CHF5.28 to CHF6.29. In the following year, the 0 analysts surveyed believe that Novartis's EPS will decrease by 8.29%, reaching CHF5.77. According to professionals, by 2030, Novartis's EPS will have decreased by 7.62%, falling down to CHF5.81.

2022 EPS Forecast
CHF5.77
2023 EPS Forecast
CHF5.62
2024 EPS Forecast
CHF5.69
2025 EPS Forecast
CHF5.89
2026 EPS Forecast
CHF5.85
2027 EPS Forecast
CHF5.77
2028 EPS Forecast
CHF5.74
2029 EPS Forecast
CHF5.79
2030 EPS Forecast
CHF5.81
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CRDA Stock Forecast Croda International Plc Outperform 18
£6.49k Buy/Sell £79.97 -98.77%
CIPLA Stock Forecast Cipla Outperform 18
Rp1.08k Buy/Sell Rp1.05k 1.08%
500124 Stock Forecast Dr. Reddy's Laboratories Outperform 18
Rp4.27k Buy/Sell Rp5.47k 15.97%